Forum for Science, Industry and Business

Sponsored by:     3M 
Search our Site:

 

Pulmonary hypertension patients improve from combination therapy

04.12.2006
For patients with pulmonary arterial hypertension (PAH), adding inhaled iloprost to treatment with bosentan—two different classes of drugs often used individually to treat PAH—increases exercise capability, reduces clinical deterioration and, in some cases, improves diagnostic functional class by one stage.

The results of this randomized, multi-center study appear in the first issue for December 2006 of the American Journal of Respiratory and Critical Care Medicine, published by the American Thoracic Society.

PAH is a debilitating and potentially fatal disease characterized by the progressive narrowing of blood vessels in the lungs. In 2000, there were 163,000 hospital discharges in which one diagnosis was PAH. Although it is more common in women, ages 21 to 40, it can affect men or women at any age.

Vallerie V. McLaughlin, M.D., of the University of Michigan Medical Center, and nine associates studied 65 PAH patients who were being treated with bosentan, an endothelin receptor antagonist that helps to increase blood flow in the lungs.

The researchers gave 32 patients both bosentan and inhaled iloprost, a prostacyclin analog. The remaining patients received bosentan and a placebo.

Every patient who received the combined therapy increased their six-minute walk distance by more than 98 feet. In addition, 11 climbed from functional class III to class II on the New York Heart Association PAH classification list, which measures how severely patients are limited by their disease. None of the patients in the combined treatment group experienced clinical deterioration by the end of the 12-week study.

Bosentan is often used for initial therapy due to its ease of administration. However, for patients who remain impaired on single drug treatment, Dr. McLaughlin calls the addition of inhaled iloprost is a “potentially attractive clinical option.”

“During the 12-week study, time to clinical worsening was significantly longer in iloprost-treated patients than in placbo patients,” she continued. “None of the iloprost patients met the predefined criteria for clinical worsening, compared with five of the 33 placebo patients.”

The investigators found the drug combination to be both safe and effective. They noted that syncope, a brief loss of consciousness due to a temporary insufficient flow of blood to the brain, was infrequent with the combination therapy, which may be an effect of bosentan.

Since inhaled iloprost therapy requires administration approximately six times per day, the researchers acknowledged that some patients could find this regimen inconvenient and expensive, given the additional cost of combining drugs.

PAH has no known cause and is difficult to diagnose. Symptoms include shortness of breath following exercise, excessive fatigue, dizziness, fainting, and weakness, with symptoms tending to worsen over time.

Suzy Martin | EurekAlert!
Further information:
http://www.thoracic.org

More articles from Health and Medicine:

nachricht Antibiotic effective against drug-resistant bacteria in pediatric skin infections
17.02.2017 | University of California - San Diego

nachricht Tiny magnetic implant offers new drug delivery method
14.02.2017 | University of British Columbia

All articles from Health and Medicine >>>

The most recent press releases about innovation >>>

Die letzten 5 Focus-News des innovations-reports im Überblick:

Im Focus: Breakthrough with a chain of gold atoms

In the field of nanoscience, an international team of physicists with participants from Konstanz has achieved a breakthrough in understanding heat transport

In the field of nanoscience, an international team of physicists with participants from Konstanz has achieved a breakthrough in understanding heat transport

Im Focus: DNA repair: a new letter in the cell alphabet

Results reveal how discoveries may be hidden in scientific “blind spots”

Cells need to repair damaged DNA in our genes to prevent the development of cancer and other diseases. Our cells therefore activate and send “repair-proteins”...

Im Focus: Dresdner scientists print tomorrow’s world

The Fraunhofer IWS Dresden and Technische Universität Dresden inaugurated their jointly operated Center for Additive Manufacturing Dresden (AMCD) with a festive ceremony on February 7, 2017. Scientists from various disciplines perform research on materials, additive manufacturing processes and innovative technologies, which build up components in a layer by layer process. This technology opens up new horizons for component design and combinations of functions. For example during fabrication, electrical conductors and sensors are already able to be additively manufactured into components. They provide information about stress conditions of a product during operation.

The 3D-printing technology, or additive manufacturing as it is often called, has long made the step out of scientific research laboratories into industrial...

Im Focus: Mimicking nature's cellular architectures via 3-D printing

Research offers new level of control over the structure of 3-D printed materials

Nature does amazing things with limited design materials. Grass, for example, can support its own weight, resist strong wind loads, and recover after being...

Im Focus: Three Magnetic States for Each Hole

Nanometer-scale magnetic perforated grids could create new possibilities for computing. Together with international colleagues, scientists from the Helmholtz Zentrum Dresden-Rossendorf (HZDR) have shown how a cobalt grid can be reliably programmed at room temperature. In addition they discovered that for every hole ("antidot") three magnetic states can be configured. The results have been published in the journal "Scientific Reports".

Physicist Dr. Rantej Bali from the HZDR, together with scientists from Singapore and Australia, designed a special grid structure in a thin layer of cobalt in...

All Focus news of the innovation-report >>>

Anzeige

Anzeige

Event News

Booth and panel discussion – The Lindau Nobel Laureate Meetings at the AAAS 2017 Annual Meeting

13.02.2017 | Event News

Complex Loading versus Hidden Reserves

10.02.2017 | Event News

International Conference on Crystal Growth in Freiburg

09.02.2017 | Event News

 
Latest News

Biocompatible 3-D tracking system has potential to improve robot-assisted surgery

17.02.2017 | Medical Engineering

Real-time MRI analysis powered by supercomputers

17.02.2017 | Medical Engineering

Antibiotic effective against drug-resistant bacteria in pediatric skin infections

17.02.2017 | Health and Medicine

VideoLinks
B2B-VideoLinks
More VideoLinks >>>